1-3 of 3
Mary-Elizabeth M. Percival
Close
Sort by
Journal Articles

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

Clinical Trials & Observations
Anna B. Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A. Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Siobán B. Keel, Paul C. Hendrie, Bart L. Scott, M. Cristina Ghiuzeli, Elihu H. Estey, Roland B. Walter
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4950–4961.
https://doi.org/10.1182/bloodadvances.2023010392
Published: 2023
Journal Articles

Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia

Clinical Trials & Observations
Ryan D. Cassaday, Kelsey-Leigh A. Garcia, Jonathan R. Fromm, Mary-Elizabeth M. Percival, Cameron J. Turtle, Paul T. Nghiem, Phillip A. Stevenson, Elihu H. Estey
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3239–3245.
https://doi.org/10.1182/bloodadvances.2020002403
Published: 2020
Includes: Supplemental data
Journal Articles

Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome

Clinical Trials & Observations
Frances Linzee Mabrey, Kelda M. Gardner, Kathleen Shannon Dorcy, Andrea Perdue, Heather A. Smith, Alicyn M. Davis, Cody Hammer, Donelle Rizzuto, Sunny Jones, Kim Quach, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Roland B. Walter, Frederick R. Appelbaum, Elihu H. Estey, Pamela S. Becker
Journal: Blood Advances
Blood Adv (2020) 4 (4): 611–616.
https://doi.org/10.1182/bloodadvances.2019000707
Published: 2020
Includes: Supplemental data